A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Trial Profile

A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Therapix Biosciences
  • Most Recent Events

    • 09 Apr 2018 According to Therapix Biosciences Ltd. media release, based on the data from a Phase IIa trial (see profile 700273303) the company is planning to this trial.
    • 07 Feb 2018 According to a Therapix Biosciences media release, company is intended to submit the IND for THX-110 via the 505(b)(2) pathway to initate trial in USA and expects to initiate the trial in second half of 2018.
    • 09 Nov 2017 According to a Therapix Biosciences media release, this study is anticipated to be conducted exclusively at the Hannover Medical School in Germany and the Company currently anticipates submitting the Investigational Medicinal Product Dossier (IMPD) for this trial by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top